Ovarian Cancer
FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)
- Details
ClinicalTrials.gov ID:
NCT02631876
Diagnosis Type:
NA
USOR Number:
17029
- Address
2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868